Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy Article Swipe

View

H. Josh Jang , Galen Hostetter , Eric A. Ross , Toshinori Hinoue , R. Katherine Alpaugh , Candice L. Schwebel , Rutika Kokate , Matthew R. Zibelman , Pooja Ghatalia , Woonbok Chung , Jean‐Pierre J. Issa , Peter A. Jones ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.30707762

Supplementary Figure 11: Peripheral immune cells are activated mid-treatment cycle.

Related Topics

My Face Hurts From Smiling

From Zero

Lunar Phase

Tales From Earthsea (Film)

Jesse (Biblical Figure)

List Of United States Senators From New York

Phase 10

Scenes From A Marriage

Postcards From The Edge (Film)

Eli (Biblical Figure)

Human From Today

Hannah (Biblical Figure)

Concepts

No concepts available.

Metadata

Type: article
Landing Page: https://doi.org/10.1158/1078-0432.30707762
OA Status: gold
OpenAlex ID: https://openalex.org/W4416671627

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416671627

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.30707762

Digital Object Identifier
Title: Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Work title
Type: article

OpenAlex work type
Publication year: 2025

Year of publication
Publication date: 2025-11-25

Full publication date if available
Authors: H. Josh Jang, Galen Hostetter, Eric A. Ross, Toshinori Hinoue, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Matthew R. Zibelman, Pooja Ghatalia, Woonbok Chung, Jean‐Pierre J. Issa, Peter A. Jones

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.30707762

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1078-0432.30707762

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416671627
doi	https://doi.org/10.1158/1078-0432.30707762
ids.doi	https://doi.org/10.1158/1078-0432.30707762
ids.openalex	https://openalex.org/W4416671627
fwci	0.0
type	article
title	Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
is_xpac	False
apc_list
apc_paid
language
locations[0].id	doi:10.1158/1078-0432.30707762
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.30707762
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5018798845
authorships[0].author.orcid	https://orcid.org/0000-0001-9654-4448
authorships[0].author.display_name	H. Josh Jang
authorships[0].author_position	first
authorships[0].raw_author_name	H. Josh Jang
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5062941900
authorships[1].author.orcid	https://orcid.org/0000-0003-2616-6861
authorships[1].author.display_name	Galen Hostetter
authorships[1].author_position	middle
authorships[1].raw_author_name	Galen Hostetter
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5048218662
authorships[2].author.orcid	https://orcid.org/0000-0002-0890-2418
authorships[2].author.display_name	Eric A. Ross
authorships[2].author_position	middle
authorships[2].raw_author_name	Eric A. Ross
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5026537645
authorships[3].author.orcid	https://orcid.org/0000-0002-5078-5016
authorships[3].author.display_name	Toshinori Hinoue
authorships[3].author_position	middle
authorships[3].raw_author_name	Toshinori Hinoue
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5049901305
authorships[4].author.orcid	https://orcid.org/0000-0002-6775-5323
authorships[4].author.display_name	R. Katherine Alpaugh
authorships[4].author_position	middle
authorships[4].raw_author_name	R. Katherine Alpaugh
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5083779488
authorships[5].author.orcid	https://orcid.org/0000-0002-2788-3486
authorships[5].author.display_name	Candice L. Schwebel
authorships[5].author_position	middle
authorships[5].raw_author_name	Candice L. Schwebel
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5033555611
authorships[6].author.orcid	https://orcid.org/0000-0002-2932-3570
authorships[6].author.display_name	Rutika Kokate
authorships[6].author_position	last
authorships[6].raw_author_name	Rutika Kokate
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5051789976
authorships[7].author.orcid	https://orcid.org/0000-0003-1475-6477
authorships[7].author.display_name	Matthew R. Zibelman
authorships[7].author_position	middle
authorships[7].raw_author_name	Matthew R. Zibelman
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5079166812
authorships[8].author.orcid	https://orcid.org/0000-0001-6229-7581
authorships[8].author.display_name	Pooja Ghatalia
authorships[8].author_position	middle
authorships[8].raw_author_name	Pooja Ghatalia
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5079853830
authorships[9].author.orcid	https://orcid.org/0000-0002-3663-8554
authorships[9].author.display_name	Woonbok Chung
authorships[9].author_position	middle
authorships[9].raw_author_name	Woonbok Chung
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5062330946
authorships[10].author.orcid	https://orcid.org/0000-0003-2258-5030
authorships[10].author.display_name	Jean‐Pierre J. Issa
authorships[10].author_position	middle
authorships[10].raw_author_name	Jean-Pierre J. Issa
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5088347458
authorships[11].author.orcid	https://orcid.org/0000-0001-8309-4767
authorships[11].author.display_name	Peter A. Jones
authorships[11].author_position	middle
authorships[11].raw_author_name	Peter A. Jones
authorships[11].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1078-0432.30707762
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-11-25T00:00:00
display_name	Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
has_fulltext	False
is_retracted	False
updated_date	2025-11-28T20:17:23.356085
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.30707762
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.30707762
primary_location.id	doi:10.1158/1078-0432.30707762
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.30707762
publication_date	2025-11-25
publication_year	2025
referenced_works_count	0
abstract_inverted_index.11:	2
abstract_inverted_index.are	6
abstract_inverted_index.cells	5
abstract_inverted_index.Figure	1
abstract_inverted_index.immune	4
abstract_inverted_index.activated	7
abstract_inverted_index.Peripheral	3
abstract_inverted_index.mid-treatment	8
abstract_inverted_index.cycle.</p>	9
abstract_inverted_index.<p>Supplementary	0
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	12
citation_normalized_percentile